...
首页> 外文期刊>European review for medical and pharmacological sciences. >Improvement of serum adiponectin and leptin concentrations: effects of a low-calorie or isocaloric diet combined with metformin or orlistat – a prospective randomized open-label trial
【24h】

Improvement of serum adiponectin and leptin concentrations: effects of a low-calorie or isocaloric diet combined with metformin or orlistat – a prospective randomized open-label trial

机译:改善血清脂联素和瘦素浓度:低热量或等热量饮食联合二甲双胍或奥利司他的效果–前瞻性随机开放试验

获取原文
           

摘要

OBJECTIVE: We compared the effects of three weight loss interventions on serum concentrations of adiponectin and leptin in obese premenopausal women. PATIENTS AND METHODS: 114 obese Caucasian women were randomized into three groups receiving a low-calorie diet (LC; n = 39), an isocaloric diet with 500 mg of metformin twice a day (IM; n = 38), and an isocaloric diet with 120 mg of orlistat three times a day (IO; n = 37), for three months. Serum concentrations of adiponectin and leptin were evaluated, along with anthropometric and body composition parameters, at baseline and after the study. RESULTS: Both IO and LC, but not IM, caused an increase in serum adiponectin concentration (p < 0.01, p < 0.05 respectively). A decrease in serum leptin level was documented in the LC (p < 0.001), IM (p < 0.01), and IO group (p < 0.01). Beneficial changes in anthropometric and body composition values were observed following all interventions with the greatest advantage seen in the IO group. The strongest correlations, of Δadiponectin with Δbody weight (r = -0.54), ΔBMI (r = -0.49), ΔFAT [%] (r = -0.48), ΔFAT [kg] (r = -0.48), and Δlean [%] (r = 0.48); and of Δleptin with Δbody weight, ΔBMI, Δwaist, Δfat, and Δlean, were documented in the IO group. CONCLUSIONS: Beneficial effects were observed on serum leptin concentration, weight loss, and body composition for all interventions and in all examined groups, with the greatest advantage being associated with the orlistat treatment. Improvements in serum adiponectin concentrations resulted from the low-calorie and isocaloric diets with orlistat, but not from the isocaloric diet with metformin. We find these strategies more promising for the treatment of obesity and its related complications in obese premenopausal women.
机译:目的:我们比较了三种减肥干预对肥胖绝经前妇女血清脂联素和瘦素浓度的影响。患者与方法:将114例肥胖的白种人女性随机分为三组,分别接受低热量饮食(LC; n = 39),每天两次含500 mg二甲双胍的等热量饮食(IM; n = 38)和等热量饮食每天3次服用120 mg奥利司他(IO; n = 37),持续三个月。在基线和研究后评估血清脂联素和瘦素的浓度,以及人体测量学和身体组成参数。结果:IO和LC均引起血清脂联素浓度增加(P <0.01,P <0.05),而非IM引起。 LC(p <0.001),IM(p <0.01)和IO组(p <0.01)的血清瘦素水平有所降低。在所有干预之后,观察到人体测量和身体成分值的有益变化,这在IO组中具有最大优势。 Δ脂联素与Δ体重(r = -0.54),ΔBMI(r = -0.49),ΔFAT[%](r = -0.48),ΔFAT[kg](r = -0.48)和Δlean[% ](r = 0.48);在IO组中记录了Δleptin和ΔBMI,Δ腰围,Δfat和Δlean的体重。结论:在所有干预措施和所有检查组中,均观察到对血清瘦素浓度,体重减轻和身体组成的有益影响,其中最大的优势与奥利司他治疗有关。血清脂联素浓度的改善是由于奥利司他的低热量和等热量饮食引起的,而不是二甲双胍的等热量饮食引起的。我们发现这些策略对于肥胖和绝经前女性的肥胖及其相关并发症的治疗更有前景。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号